ALBAN: An open label, randomized, phase III trial, evaluating efficacy of atezolizumab in addition to one year BCG (bacillus Calmette-Guerin) bladder instillation in BCG-naive patients with high-risk nonmuscle invasive bladder cancer (AFU-GETUG 37).

Affiliation auteurs!!!! Error affiliation !!!!
TitreALBAN: An open label, randomized, phase III trial, evaluating efficacy of atezolizumab in addition to one year BCG (bacillus Calmette-Guerin) bladder instillation in BCG-naive patients with high-risk nonmuscle invasive bladder cancer (AFU-GETUG 37).
Type de publicationJournal Article
Year of Publication2019
AuteursRoupret M, Neuzillet Y, Bertaut A, Pignot G, Houede N, Champiat S, Le Ficher SNenan-, Chausson M, Loriot Y
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume37
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/JCO.2019.37.15_suppl.TPS4589